Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2013-03-20 Investor Presentation
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
CEO on Strategy - Audio Interview 1 page 102.3KB
Investor Presentation Classification · 90% confidence The document is an Open Briefing broadcast featuring the CEO discussing company strategy, product science, market size, and cash position. It is a summary communication intended for investors and the market, not a detailed financial report or regulatory filing. The document length is short (1902 characters) and it does not contain financial statements or detailed analysis. It is not an earnings release or annual/interim report. It is also not a transcript of a call but rather a briefing announcement with a link to listen to the broadcast. Therefore, the best fit is Investor Presentation (IP), as it focuses on company strategy and market information for investors.
2013-03-20 English
Living Cell Technologies Awarded NZBIO Company of the Year 2 pages 172.5KB
Regulatory Filings Classification · 95% confidence The document is a company announcement from Living Cell Technologies Limited about receiving an industry award (NZBIO Company of the Year). It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, no capital or financing updates, and no legal or merger information. It is a press release-style announcement focused on company recognition and business development achievements. The document length is 6896 characters, which is sufficient for a detailed announcement but does not contain financial or regulatory report content. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2013-03-19 English
Appendix 4D and Half-Year Accounts 21 pages 230.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D' and is described as a 'Half yearly report' for the financial period ended 31 December 2012. It contains detailed financial statements including a consolidated statement of profit and loss, directors' report, auditor's independence declaration, and notes to the consolidated financial statements. The presence of comprehensive financial data and analysis for a half-year period, along with the auditor's review report, indicates this is a formal interim financial report. The document is approximately 15,000 characters long, which is consistent with a full interim report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2013
2013-02-26 English
Announcement on Half-Year Report 2 pages 30.4KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'LCT Half Yearly Report period ended 31 December 2012' and contains detailed financial and operational information for the six months ended 31 December 2012. It includes financial figures such as operating loss, profit, service fees, research and development costs, joint venture losses, net assets, and cash equivalents. The document is 6601 characters long, which is sufficient to contain substantive financial data and analysis. It is not merely an announcement of a report being published or attached; rather, it presents actual financial results and business updates for the half-year period. Therefore, this document fits the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data and analysis. H1 2013
2013-02-26 English
Change of Director's Interest Notice 2 pages 73.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares held before and after the change, the nature of the transaction (on-market trade), and dates. This is a report of personal share transactions by a company director, which fits the definition of Director's Dealing filings. The document length is 3284 characters, which is consistent with a detailed notice rather than a brief announcement or a full report. Therefore, the correct classification is Director's Dealing (DIRS).
2013-02-11 English
Appendix 4C - quarterly 7 pages 69.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report 31 December 2012' and contains detailed quarterly cash flow statements, including operating, investing, and financing activities. It includes financial figures for the quarter ended 31 December 2012 and year-to-date, as well as reconciliations of cash and notes on compliance with accounting standards. The document is over 13,000 characters, indicating it is a substantive financial report rather than a brief announcement. The Appendix 4C is a recognized quarterly report format used by entities admitted on the basis of commitments, consistent with interim or quarterly reporting. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q2 2013
2013-01-29 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.